Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Nanterre, France Clinical Trials

A listing of Nanterre, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (11) clinical trials

A Study of Benralizumab in Patients With Eosinophilic Esophagitis

The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment period (including a 24-week double-blind placebo-controlled treatment period and a …

Phase

1.57 miles

Learn More »

Effect of Naloxegol on Postoperative Ileus in Patients Undergoing Cardiac Surgery

Digestive complications following cardiac surgery, such as paralytic ileus and Ogilvie syndrome, are frequent and worsen the prognosis of patients. They pose a real problem of care in intensive care, inducing morbidity and mortality, extended hospital stay and a significant post-operative cost. Few treatments are effective to reduce transit recovery …

Phase

2.32 miles

Learn More »

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

CAB LA + RPV LA is an investigational HIV-1 treatment regimen administered as two individual intramuscular injections every 2 months following an oral lead-in (OLI) period. The overall objective of the CAB LA + RPV LA clinical development program is to develop a highly effective, well-tolerated, two-drug, LA injectable regimen …

Phase

6.25 miles

Learn More »

SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism

Rheumatoid arthritis (RA) and spondyloarthritis (SPA) are the two most common chronic inflammatory rheumatic diseases, with a prevalence of 0.5-1% for RA and about 0.35% for SPA. Many studies have described an increased risk of serious infectious diseases directly associated with increased morbidity and mortality among those patients. This increased …

Phase N/A

6.55 miles

Learn More »

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC). Study drug BAY1817080 is a new drug under development for the treatment of long-standing cough. It blocks proteins that are …

Phase

6.69 miles

Learn More »

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Worldwide, lung cancer is the most commonly diagnosed cancer. In NSCLC the most prevalent actionable driver mutations result in the activation of epidermal growth factor receptor (EGFR). Osimertinib and Lazertinib are EGFR tyrosine kinase inhibitors (TKIs). Amivantamab is a novel bispecific antibody that targets the extracellular domain of both EGFR …

Phase

6.69 miles

Learn More »

Effectiveness of Music Therapy on Sleep Disorders

Sleep is a key factor in a person's health, and we actually spend one third of our lives sleeping. The latest figures show a prevalence of insomnia in 20-30% of French adults. Sleep disorders are a growing public health concern. Treatment for insomnia is often some form of drugs; however, …

Phase N/A

7.37 miles

Learn More »

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

This is an international, multicenter, open-label, long term extension study evaluating the safety of ecopipam tablets for the treatment of pediatric subjects (aged 6 to 18 years at Baseline) with Tourette Syndrome. Subjects who completed the Phase 2b, randomized, double-blind, efficacy and safety study (EBS-101-CL-001) without major reportable protocol deviations, …

Phase

7.79 miles

Learn More »

Safety Tolerability and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.

Phase

7.81 miles

Learn More »

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Phase

7.81 miles

Learn More »